Rosalind Advisors, Inc. - Oct 30, 2024 Form 4 Insider Report for DELCATH SYSTEMS, INC. (DCTH)

Role
Director
Signature
Steven Salamon
Stock symbol
DCTH
Transactions as of
Oct 30, 2024
Transactions value $
$500,000
Form type
4
Date filed
11/1/2024, 03:07 PM
Previous filing
May 16, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DCTH Tranche B warrants to purchase F-4 Preferred Stock Options Exercise $500K +500 $1,000.00 0 Oct 30, 2024 F-4 PREFERRED STOCK 500 $1,000.00 By Rosalind Advisors, Inc., the advisor to the Rosalind Funds F1, F2, F3
transaction DCTH 8% CONVERTIBLE NOTE Expiration (or cancellation) of long derivative position with value received $0 0 $0.00 0 Oct 30, 2024 CASH $1.42M $0.00 By Rosalind Advisors, Inc., the advisor to the Rosalind Funds F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately exercisable
F2 The Tranche B Warrants expire the earlier of (i) twenty-one (21) days following the date of the Issuer's public announcement of record at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and (ii) March 31, 2026. The Issuer announced on October 17, 2024 that it had recorded at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and therefore such Tranche B Warrants expire on November 7, 2024.
F3 Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein
F4 Delcath repaid the DELCATH SYSTEM - 8% CONVERTIBLE NOTE in full with cash of $1,423,333.
F5 N/A